Brunner, HI; Bennett, MR; Gulati, G; Abulaban, K; Klein-Gitelman, MS; Ardoin, SP; Tucker, LB; Rouster-Stevens, KA; Witte, D; Ying, J; Devarajan, P. Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults. The Journal of rheumatology. 2017; 44(8):1239-1248.
This is the first report of a combination of non-invasive urinary biomarkers which can be useful to predict response to treatment of lupus nephritis in children and adults. Not only was the biomarker panel discovered, but also validated in this collaborative study involving nephrology and rheumatology.
Pleasant, L; Ma, Q; Devarajan, M; Parameswaran, P; Drake, K; Siroky, B; Shay-Winkler, K; Robbins, J; Devarajan, P. Increased susceptibility to structural acute kidney injury in a mouse model of presymptomatic cardiomyopathy. American Journal of Physiology: Renal Physiology. 2017; 313(3):F699-F705.
This is the first demonstration of subclinical kidney damage that occurs in an animal model of mild heart failure. The study identified novel mechanisms that lead to kidney injury in this common susceptible population of infants and children.
Nehus, E; Kaddourah, A; Bennett, M; Pyles, O; Devarajan, P. Subclinical Kidney Injury in Children Receiving Nonsteroidal Anti-Inflammatory Drugs After Cardiac Surgery. The Journal of Pediatrics. 2017; 189:175-180.
This is the first demonstration of the use of a novel non-invasive biomarker to identify subclinical kidney damage due to NSAID drugs in children, which is very common in clinical practice.
Varnell, CD, JR; Goldstein, SL; Devarajan, P; Basu, RK. Impact of Near Real-Time Urine Neutrophil Gelatinase–Associated Lipocalin Assessment on Clinical Practice. Kidney International Reports. 2017; 2(6):1243-1249.
This is the first practical demonstration of the use of a novel urinary biomarker in real time for the early diagnosis, management, and prognosis of kidney injury in children.
Mitsnefes, MM; Betoko, A; Schneider, MF; Salusky, IB; Wolf, MS; Juppner, H; Warady, BA; Furth, SL; Portale, AA. FGF23 and Left Ventricular Hypertrophy in Children with CKD. Clinical journal of the American Society of Nephrology : CJASN. 2018; 13(1):45-52.
This is the first study to examine the role of FGF23 as a marker of left ventricular hypertrophy in children with chronic kidney disease.